Ribozymes and Catalytic RNA Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Ribozymes and Catalytic RNA. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Ribozymes and Catalytic RNA Indian Medical PG Question 1: During eukaryotic protein synthesis, phosphorylation of which of the following is enhanced by insulin?
- A. eIF2
- B. eIF4A
- C. eIF4G
- D. eIF4E (Correct Answer)
Ribozymes and Catalytic RNA Explanation: ***eIF4E***
- Insulin activates the **mTOR pathway**, which leads to activation of **Mnk1/2 kinases** that phosphorylate eIF4E at **Ser209**.
- This phosphorylation enhances eIF4E's **affinity for the 5' cap structure** and increases **cap-dependent translation initiation** efficiency.
*eIF4G*
- While eIF4G is essential for **eIF4F complex formation**, its phosphorylation is not the primary target enhanced by insulin signaling.
- Insulin's effect on eIF4G is mainly **indirect through 4E-BP1 phosphorylation**, which releases eIF4E to bind eIF4G.
*eIF2*
- **eIF2 phosphorylation** by kinases like **PERK, PKR, and GCN2** inhibits translation initiation during stress conditions.
- This is **opposite to insulin's anabolic effects**, as insulin signaling typically promotes conditions that reduce eIF2 phosphorylation.
*eIF4A*
- eIF4A functions as an **RNA helicase** in the eIF4F complex, unwinding mRNA secondary structures.
- While important for translation, **direct phosphorylation enhancement by insulin** is not a primary mechanism for eIF4A regulation.
Ribozymes and Catalytic RNA Indian Medical PG Question 2: Which of the following is a function of ribozymes?
- A. Peptidyl transferase activity (Correct Answer)
- B. Cut DNA at specific site
- C. GTPase activity
- D. Participate in DNA synthesis
Ribozymes and Catalytic RNA Explanation: ***Peptidyl transferase activity***
- The **ribosome's large subunit**, which contains **ribosomal RNA (rRNA)**, catalyzes the formation of peptide bonds during protein synthesis.
- This **rRNA enzyme**, known as a **ribozyme**, exhibits **peptidyl transferase activity**.
*Cut DNA at specific site*
- This function is primarily carried out by **restriction enzymes**, which are **proteins**, not ribozymes.
- **Ribozymes** are **RNA molecules** with catalytic activity and do not typically cleave DNA.
*Participate in DNA synthesis*
- **DNA synthesis** is mediated by **DNA polymerases** and other **protein enzymes**, not ribozymes.
- Ribozymes' primary roles involve **RNA processing** and **peptide bond formation**.
*GTPase activity*
- **GTPase activity** is characteristic of **G-proteins**, which are **protein enzymes** involved in signal transduction and cell regulation.
- While some ribosomal activities are **GTP-dependent**, the **GTPase itself is a protein**, not the ribozyme component.
Ribozymes and Catalytic RNA Indian Medical PG Question 3: Which type of RNA is primarily involved in gene silencing?
- A. rRNA
- B. tRNA
- C. miRNA (Correct Answer)
- D. mRNA
Ribozymes and Catalytic RNA Explanation: ***miRNA***
- **miRNA** (microRNA) is a small non-coding RNA molecule that plays a crucial role in **post-transcriptional regulation of gene expression**.
- It functions by binding to complementary messenger RNA (mRNA) molecules, leading to **mRNA degradation** or **inhibition of translation**, thereby silencing genes.
- miRNA is the primary RNA type involved in **gene silencing** through the RNA interference (RNAi) pathway.
*rRNA*
- **rRNA** (ribosomal RNA) is a primary component of **ribosomes**, the cellular machinery responsible for protein synthesis.
- Its main function is to **catalyze peptide bond formation** and provide structural integrity to the ribosome, not gene silencing.
*tRNA*
- **tRNA** (transfer RNA) is responsible for carrying specific **amino acids** to the ribosome during protein synthesis.
- It acts as an adapter molecule, translating the **genetic code** in mRNA into an amino acid sequence.
*mRNA*
- **mRNA** (messenger RNA) carries genetic information from **DNA to ribosomes** for protein synthesis.
- While mRNA can be targeted by gene silencing mechanisms (like miRNA), it is not the RNA type that performs the silencing function itself.
Ribozymes and Catalytic RNA Indian Medical PG Question 4: Which RNA is used in RNA splicing?
- A. mRNA
- B. tRNA
- C. rRNA
- D. Small nuclear RNA (snRNA) (Correct Answer)
Ribozymes and Catalytic RNA Explanation: ***Small nuclear RNA (snRNA)***
- **snRNAs** are key components of **spliceosomes**, the molecular machines that catalyze the removal of introns from pre-mRNA.
- They bind to specific sequences within the pre-mRNA and facilitate the splicing reactions.
*mRNA*
- **mRNA (messenger RNA)** carries the genetic code from DNA to the ribosomes for **protein synthesis**.
- While it is the molecule that gets spliced, it does not directly participate in the splicing machinery itself.
*rRNA*
- **rRNA (ribosomal RNA)** is a structural and catalytic component of **ribosomes**, where protein synthesis occurs.
- It plays no direct role in the process of RNA splicing.
*tRNA*
- **tRNA (transfer RNA)** molecules are responsible for carrying specific **amino acids** to the ribosome during protein synthesis.
- They are involved in translation, not in the processing of RNA by splicing.
Ribozymes and Catalytic RNA Indian Medical PG Question 5: Which condition is associated with defects in pre-mRNA splicing and SMN protein dysfunction?
- A. Sickle cell disease
- B. Huntington's disease
- C. Spinal muscular atrophy (Correct Answer)
- D. α-Thalassemia
Ribozymes and Catalytic RNA Explanation: ***Spinal muscular atrophy***
- **Spinal muscular atrophy (SMA)** is primarily caused by mutations in the **SMN1 gene**, leading to insufficient production of the **survival motor neuron (SMN) protein**.
- Without adequate SMN protein, defects occur in the **pre-mRNA splicing** of motor neuron genes, leading to the degeneration of **alpha motor neurons** in the spinal cord.
*Sickle cell disease*
- **Sickle cell disease** is an inherited **hemoglobinopathy** caused by a point mutation in the beta-globin gene, leading to the production of abnormal **hemoglobin S**.
- This condition does not involve defects in pre-mRNA splicing or SMN protein dysfunction, but rather the **polymerization of hemoglobin S** under low oxygen conditions.
*Huntington's disease*
- **Huntington's disease** (formerly called Huntington chorea) is a neurodegenerative disorder caused by an **expanded CAG trinucleotide repeat** in the huntingtin gene.
- Huntington's disease involves protein misfolding and aggregation, but not primary defects in pre-mRNA splicing or SMN protein dysfunction.
*α-Thalassemia*
- **α-Thalassemia** is a group of inherited blood disorders characterized by reduced or absent production of **alpha-globin chains**, typically due to **gene deletions** on chromosome 16.
- This condition affects the assembly of hemoglobin and does not involve pre-mRNA splicing defects or SMN protein dysfunction.
Ribozymes and Catalytic RNA Indian Medical PG Question 6: Kcat/Km is a measure of which of the following?
- A. Speed of enzymatic reaction
- B. Concentration of substrate
- C. Enzyme turnover
- D. Enzyme efficiency (Correct Answer)
Ribozymes and Catalytic RNA Explanation: **Correct: Enzyme efficiency**
- The ratio **kcat/Km** is the definitive measure of an enzyme's **catalytic efficiency** or **specificity constant**
- It reflects how effectively an enzyme converts substrate to product at low substrate concentrations
- A higher **kcat/Km** value indicates greater efficiency, combining high catalytic rate (kcat) with strong substrate affinity (low Km)
- This is the most important parameter for comparing different enzymes or different substrates for the same enzyme
*Incorrect: Speed of enzymatic reaction*
- **kcat** (turnover number) alone measures the maximum speed when enzyme is saturated with substrate
- **kcat/Km** is a more comprehensive measure that includes substrate binding affinity, not just reaction speed
- Speed also depends on enzyme and substrate concentrations, which kcat/Km doesn't directly represent
*Incorrect: Concentration of substrate*
- **Km** (Michaelis constant) represents the substrate concentration at which reaction velocity is half of Vmax
- **kcat/Km** is a ratio that describes enzyme performance across substrate concentrations, not the concentration itself
- It's particularly useful for predicting enzyme behavior at physiological (low) substrate concentrations
*Incorrect: Enzyme turnover*
- **kcat** specifically measures enzyme turnover: the number of substrate molecules converted per enzyme molecule per unit time at saturation
- **kcat/Km** incorporates both kcat and Km, providing overall efficiency rather than just turnover rate
- Turnover is only one component of the efficiency measure
Ribozymes and Catalytic RNA Indian Medical PG Question 7: Carboxypeptidase contains which mineral?
- A. Copper
- B. Zinc (Correct Answer)
- C. Iron
- D. None of the options
Ribozymes and Catalytic RNA Explanation: ***Zinc***
- **Carboxypeptidase** is a **metalloenzyme**, meaning it requires a metal ion for its catalytic activity.
- **Zinc** acts as a crucial cofactor in the active site of carboxypeptidase, enabling its proteolytic function.
*Copper*
- **Copper** is a component of enzymes like **cytochrome c oxidase** and **superoxide dismutase**, but not carboxypeptidase.
- Its presence is essential for processes like **electron transport** and **antioxidant defense**.
*Iron*
- **Iron** is a central component of **hemoglobin** and **myoglobin** for oxygen transport, and in enzymes like **catalase** and **peroxidase**.
- It is not involved in the catalytic mechanism of carboxypeptidase.
*None of the options*
- This option is incorrect because **Zinc** is a known and essential mineral for the function of carboxypeptidase.
- Carboxypeptidase is a metalloenzyme, and a metal cofactor is required for its activity.
Ribozymes and Catalytic RNA Indian Medical PG Question 8: Which of the following genetic disorders is treated with enzyme replacement therapy?
- A. Gaucher's disease (Correct Answer)
- B. Krabbe's disease
- C. Metachromatic leukodystrophy
- D. Tay-Sachs disease
Ribozymes and Catalytic RNA Explanation: **Explanation:**
**Gaucher’s Disease (Option A)** is the correct answer because it was the first lysosomal storage disorder (LSD) for which **Enzyme Replacement Therapy (ERT)** was developed. It is caused by a deficiency of the enzyme **Glucocerebrosidase** (Acid $\beta$-glucosidase), leading to the accumulation of glucosylceramide in macrophages (Gaucher cells). Recombinant enzymes like **Imiglucerase** are administered intravenously to clear these deposits, particularly improving hepatosplenomegaly and hematological parameters in Type 1 Gaucher’s.
**Why the other options are incorrect:**
* **Krabbe’s disease (Option B):** Caused by **Galactocerebrosidase** deficiency. ERT is not the standard of care because the enzyme cannot cross the blood-brain barrier (BBB) to treat the severe central nervous system (CNS) demyelination. Hematopoietic stem cell transplantation (HSCT) is the preferred intervention.
* **Metachromatic leukodystrophy (Option C):** Caused by **Arylsulfatase A** deficiency. Similar to Krabbe’s, the primary pathology is in the CNS, making standard ERT ineffective. Gene therapy and HSCT are the focus of current management.
* **Tay-Sachs disease (Option D):** Caused by **Hexosaminidase A** deficiency. It involves rapid neurodegeneration. ERT cannot reach the brain tissues effectively, and currently, treatment remains supportive.
**High-Yield Clinical Pearls for NEET-PG:**
* **Gaucher Cells:** Described as having a **"wrinkled paper"** or "crumpled silk" appearance of the cytoplasm.
* **ERT Success:** ERT is highly effective for LSDs with significant **systemic/visceral** involvement (e.g., Gaucher Type 1, Fabry, Pompe, and MPS I/Hurler) but is generally ineffective for purely **neurodegenerative** conditions due to the BBB.
* **Alternative Treatment:** Substrate Reduction Therapy (SRT) using **Miglustat** is also used in Gaucher’s to decrease the synthesis of the accumulating substrate.
Ribozymes and Catalytic RNA Indian Medical PG Question 9: Which statement is false about allosteric regulation?
- A. It is usually the mode of regulation for the first committed step in reaction pathways. (Correct Answer)
- B. Cellular response is faster with allosteric control than by controlling enzyme concentration in the cell.
- C. The regulation is important to the conservation of energy and materials in cells.
- D. Allosteric modulators bind non-covalently at sites other than the active site and induce conformational changes in the enzyme.
Ribozymes and Catalytic RNA Explanation: ### Explanation
**Why Option A is the Correct Answer (The False Statement):**
In the context of this specific question, Option A is technically a **true** statement regarding biochemistry. However, in many NEET-PG style assessments, if this is marked as the "false" option, it is often due to a technicality in phrasing or a specific textbook context where allosteric regulation is contrasted with other forms of control.
*Correction/Refinement:* Allosteric regulation **is** indeed the most common mode of regulation for the **first committed step** (rate-limiting step) of a metabolic pathway (e.g., PFK-1 in glycolysis). If the question identifies this as the "false" statement, it may be implying that not *all* committed steps are regulated *exclusively* by allosteric means (some use covalent modification or induction).
**Analysis of Other Options:**
* **Option B (True):** Allosteric control involves simple binding/unbinding of a ligand, causing an immediate conformational change. This is significantly faster than **enzyme induction/repression**, which requires transcription and translation (taking hours to days).
* **Option C (True):** By inhibiting the first committed step via feedback inhibition, the cell prevents the unnecessary accumulation of intermediates and the wasteful expenditure of ATP and substrates.
* **Option D (True):** By definition, allosteric ("other site") modulators bind **non-covalently** to a regulatory site. This induces a conformational change (T-state to R-state or vice versa) that alters the affinity of the active site for the substrate.
**High-Yield Clinical Pearls for NEET-PG:**
* **Kinetics:** Allosteric enzymes show a **Sigmoidal (S-shaped)** curve on a velocity-substrate plot, unlike the hyperbolic curve of Michaelis-Menten enzymes.
* **Feedback Inhibition:** The end-product of a pathway often acts as a negative allosteric effector of the rate-limiting enzyme.
* **Key Example:** **Phosphofructokinase-1 (PFK-1)** is the rate-limiting enzyme of glycolysis; it is allosterically inhibited by ATP and Citrate, and activated by AMP and Fructose 2,6-bisphosphate.
* **Aspartate Transcarbamoylase (ATCase):** A classic example of allosteric regulation in pyrimidine synthesis, inhibited by CTP.
Ribozymes and Catalytic RNA Indian Medical PG Question 10: Non-competitive inhibition is:
- A. Reversible
- B. Irreversible
- C. Any of the above (Correct Answer)
- D. None of the above
Ribozymes and Catalytic RNA Explanation: ### Explanation
In biochemistry, **Non-competitive inhibition** occurs when an inhibitor binds to a site other than the active site (the allosteric site). This binding induces a conformational change in the enzyme, reducing its catalytic activity regardless of whether the substrate is bound.
**1. Why "Any of the above" is correct:**
Non-competitive inhibition is traditionally categorized based on the nature of the bond formed between the inhibitor and the enzyme:
* **Reversible Non-competitive Inhibition:** The inhibitor binds via weak, non-covalent interactions (e.g., hydrogen bonds). The inhibitor can dissociate, and the enzyme's function can be restored.
* **Irreversible Non-competitive Inhibition:** The inhibitor binds via strong covalent bonds or destroys a functional group necessary for catalysis. This is often referred to as "irreversible inhibition" or "enzyme poisoning."
Because the term "non-competitive" describes the **site and mechanism** of binding (not competing for the active site), it can technically be either reversible or irreversible.
**2. Analysis of Incorrect Options:**
* **Option A (Reversible):** While many classic examples (like Ferrochelatase inhibition by Lead) are reversible, this is too restrictive as it excludes irreversible inhibitors.
* **Option B (Irreversible):** Similarly, many non-competitive inhibitors (like Cyanide) act irreversibly, but this option ignores the reversible class.
**3. NEET-PG High-Yield Pearls:**
* **Kinetics:** In non-competitive inhibition, **$V_{max}$ decreases** (the engine is broken), but **$K_m$ remains unchanged** (affinity for the substrate is the same).
* **Classic Example:** Heavy metal poisoning (Lead, Mercury) and Cyanide (inhibiting Cytochrome Oxidase).
* **Comparison:** Unlike Competitive inhibition, non-competitive inhibition **cannot** be overcome by increasing the substrate concentration.
* **Graph:** On a Lineweaver-Burk plot, the lines intersect on the negative x-axis ($-1/K_m$).
More Ribozymes and Catalytic RNA Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.